Literature DB >> 1699901

Expression of PDGF beta-receptors in human meningioma cells.

J L Wang1, M Nistér, M Hermansson, B Westermark, J Pontén.   

Abstract

Meningioma is a generally benign tumor derived from arachnoid tissue. We have investigated the presence of functionally active PDGF-receptors on human meningioma cells in culture. Tumor samples were obtained from 3 surgically removed benign meningiomas and normal arachnoid tissue from an autopsy case. Binding studies were performed by using 125I-labelled recombinant PDGF-AA and PDGF-BB. Only 125I-PDGF-BB showed specific binding to all tumor-cell cultures after incubation of cells for 2 hr at 4 degrees C. Effects of PDGF-AA and PDGF-BB on DNA synthesis were measured as 3H-thymidine incorporation during 48 hr of labelling cells maintained in Eagle's minimum essential medium 0.5% fetal calf serum. PDGF-BB but not PDGF-AA stimulated DNA synthesis in all 3 tumor-cell cultures. Total cellular RNA was analyzed by Northern blotting and hybridization with a 32P-labelled human PDGF beta-receptor probe, and PDGF beta-receptor mRNA was found in both tumor and arachnoid cell cultures. Furthermore, PDGF beta-receptor mRNA was shown to be present in 2 meningioma biopsies and immunohistochemical staining revealed that PDGF beta-receptors are present in meningioma and arachnoid tissues in vivo. It appears that a possible way of maintaining human meningioma cell growth in vivo is through activation of PDGF beta-receptors.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1699901     DOI: 10.1002/ijc.2910460504

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  19 in total

1.  Down-regulation of cellular platelet-derived growth factor receptors induced by an activated neu receptor tyrosine kinase.

Authors:  L Lehtola; M Nistér; E Hölttä; B Westermark; K Alitalo
Journal:  Cell Regul       Date:  1991-08

Review 2.  New prospects for management and treatment of inoperable and recurrent skull base meningiomas.

Authors:  Mahlon D Johnson; Burak Sade; Michael T Milano; Joung H Lee; Steven A Toms
Journal:  J Neurooncol       Date:  2007-07-12       Impact factor: 4.130

Review 3.  Platelet-derived growth factor in human brain tumors.

Authors:  M Kirsch; J C Wilson; P Black
Journal:  J Neurooncol       Date:  1997-12       Impact factor: 4.130

4.  Imatinib mesylate treatment of recurrent meningiomas in preselected patients: a retrospective analysis.

Authors:  Peter Horak; Adelheid Wöhrer; Marco Hassler; Johannes Hainfellner; Matthias Preusser; Christine Marosi
Journal:  J Neurooncol       Date:  2012-05-20       Impact factor: 4.130

5.  Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08).

Authors:  Patrick Y Wen; W K Alfred Yung; Kathleen R Lamborn; Andrew D Norden; Timothy F Cloughesy; Lauren E Abrey; Howard A Fine; Susan M Chang; H Ian Robins; Karen Fink; Lisa M Deangelis; Minesh Mehta; Emmanuelle Di Tomaso; Jan Drappatz; Santosh Kesari; Keith L Ligon; Ken Aldape; Rakesh K Jain; Charles D Stiles; Merrill J Egorin; Michael D Prados
Journal:  Neuro Oncol       Date:  2009-12       Impact factor: 12.300

6.  Expression of PDGF, PDGF-receptor, EGF-receptor and sex hormone receptors on meningioma.

Authors:  J I Kuratsu; H Seto; M Kochi; Y Ushio
Journal:  Acta Neurochir (Wien)       Date:  1994       Impact factor: 2.216

7.  Neurotrophic activity of platelet-derived growth factor (PDGF): Rat neuronal cells possess functional PDGF beta-type receptors and respond to PDGF.

Authors:  A Smits; M Kato; B Westermark; M Nistér; C H Heldin; K Funa
Journal:  Proc Natl Acad Sci U S A       Date:  1991-09-15       Impact factor: 11.205

Review 8.  Medical management of meningiomas.

Authors:  Wendy J Sherman; Jeff J Raizer
Journal:  CNS Oncol       Date:  2013-03

9.  Expression of platelet-derived growth factor and its receptor in AIDS-related Kaposi sarcoma in vivo suggests paracrine and autocrine mechanisms of tumor maintenance.

Authors:  M Stürzl; W K Roth; N H Brockmeyer; C Zietz; B Speiser; P H Hofschneider
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-01       Impact factor: 11.205

10.  Tissue platelet derived-growth factor (PDGF) predicts for shortened survival and treatment failure in advanced breast cancer.

Authors:  L Seymour; D Dajee; W R Bezwoda
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.